Research Topics
| Michael J SchellSummaryAffiliation: H. Lee Moffitt Cancer Center and Research Institute Country: USA Publications
| Collaborators
|
Detail Information
Publications
Evidence-based target recall rates for screening mammographyMichael J Schell
Biostatistics Division, Department of Interdisciplinary Oncology, Moffitt Research Center, 12902 Magnolia Dr, Tampa, FL 33612 9497, USA
Radiology 243:681-9. 2007..To retrospectively identify target recall rates for screening mammography on the basis of how sensitivity shifts with recall rate...
Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancerZhong Zheng
Program and Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 9497, USA
Cancer 112:2765-73. 2008..We hypothesized that intratumoral TS expression would be prognostic of outcome in stage I NSCLC...
Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancerAlberto A Chiappori
Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
J Thorac Oncol 5:484-90. 2010..Our aim was to determine the expression levels of these proteins to assess their potential clinical utility in SCLC...- Analysis of group randomized trials with multiple binary endpoints and small number of groupsJi Hyun Lee
Biostatistics Core, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America
PLoS ONE 4:e7265. 2009..The multiple endpoints from the GRT design are analyzed using a generalized linear mixed model and the stepdown Bonferroni method of Holm... - A predictive risk probability approach for microarray data with survival as an endpointDung Tsa Chen
Biostatistics Division, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
J Biopharm Stat 18:841-52. 2008..Third, analysis of resampling the risk probability suggested the variation pattern of the log-rank chi(2) in the colon cancer data set was unlikely caused by chance... - Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or olderGeorge R Simon
Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
Cancer 112:2021-9. 2008..The primary endpoint was response rate (RR). Secondary endpoints were overall survival (OS) and progression-free survival (PFS)... - Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancerEric B Haura
Department of Thoracic Oncology and Biostatistics, Clinical Trials and Clinical Pharmacology Core, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
J Clin Oncol 28:1387-94. 2010.... - Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysisTawee Tanvetyanon
Biostatistics Division, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Dr, Tampa, FL 33613, USA
J Clin Oncol 26:1142-7. 2008..However, some suggest that the survival outcome among patients with a synchronous metastasis is poor. It remains unclear whether this treatment approach is warranted among those with synchronous metastasis... - Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cellsJingchun Gao
Department of Experimental Therapeutics and Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612 9497, USA
Cancer Biol Ther 8:1671-9. 2009..These results suggest that Mirk is overexpressed in lung cancer, acts as a survival factor in lung cancer cells and may be a novel therapeutic target... - ABCG2 expression, function, and promoter methylation in human multiple myelomaJoel G Turner
H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL 33612, USA
Blood 108:3881-9. 2006..These findings suggest that ABCG2 is expressed and functional in human myeloma cells, regulated by promoter methylation, affected by cell density, up-regulated in response to chemotherapy, and may contribute to intrinsic drug resistance... - Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancerJian Ping Guo
Departments of Molecular Oncology, H Lee Moffitt Cancer Center, Tampa, Florida 33612, USA
Am J Pathol 175:324-33. 2009..IKKepsilon could also serve as a prognostic marker and potential therapeutic target for this malignancy... - Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxelMark A Socinski
Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
Cancer 95:1265-73. 2002..The authors sought to determine the activity of second-line, low-dose, weekly paclitaxel in patients with NSCLC who failed first-line chemotherapy with carboplatin plus paclitaxel... - The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxelThomas A Hensing
Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
Cancer 98:779-88. 2003.... - Recall and detection rates in screening mammographyBonnie C Yankaskas
Cancer 101:2710-1; author reply 2711-2. 2004 - Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancerThomas A Hensing
Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
Lung Cancer 47:253-9. 2005..Factors increasing the likelihood of second-line therapy include high performance status, female gender and non-squamous histology, while early termination of first-line therapy decreased the likelihood of further therapy... - Comparison of three methods to increase knowledge about breast cancer and breast cancer screening in screening mammography patientsDag Pavic
Department of Radiology, University of North Carolina at Chapel Hill, CB 7510, Chapel Hill, NC 27599 7510, USA
Acad Radiol 14:553-60. 2007..The specific aim of the study was to determine which of several cost-effective interventions is best able to improve the breast cancer knowledge of women who present for screening mammography... - Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancerMark A Socinski
Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
J Clin Oncol 20:1335-43. 2002..To compare four cycles of therapy versus continuous therapy to determine the optimal duration of chemotherapy in advanced non-small-cell lung cancer (NSCLC)... - Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance statusThomas E Stinchcombe
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
Lung Cancer 51:237-43. 2006.... - Factors predicting successful needle-localized breast biopsyPage E Abrahamson
Department of Epidemiology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
Acad Radiol 10:601-6. 2003..02), and decreased specimen volume (P = .03). CONCLUSION: Needle localization wires should be placed within 5 mm of mammographically visible lesions to increase the probability of successful lesion excision...